Transmission of HIV-1 drug-resistant variants: prevalence and effect on treatment outcome.
暂无分享,去创建一个
[1] Gregory S Turenchalk,et al. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. , 2009, The Journal of infectious diseases.
[2] Matthias Cavassini,et al. Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[3] Rodolphe Thiébaut,et al. Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy , 2008, AIDS.
[4] Michael Monsour,et al. Minority HIV-1 Drug Resistance Mutations Are Present in Antiretroviral Treatment–Naïve Populations and Associate with Reduced Treatment Efficacy , 2008, PLoS medicine.
[5] D. Richman,et al. Persistence of Transmitted Drug Resistance among Subjects with Primary Human Immunodeficiency Virus Infection , 2008, Journal of Virology.
[6] Spread programme,et al. Transmission of drug-resistant HIV-1 in Europe remains limited to single classes , 2008, AIDS.
[7] Wei Shao,et al. Frequent polymorphism at drug resistance sites in HIV-1 protease and reverse transcriptase , 2008, AIDS.
[8] H. Jessen,et al. Impact of transmission of drug‐resistant HIV on the course of infection and the treatment success. Data from the German HIV‐1 Seroconverter Study , 2007, HIV medicine.
[9] M. Tolstrup,et al. Dynamics of 103K/N and 184M/V HIV-1 drug resistant populations: relative comparison in plasma virus RNA versus CD45RO+T cell proviral DNA. , 2007, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[10] A. Geretti,et al. Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. , 2007, The Journal of antimicrobial chemotherapy.
[11] M. Zazzi,et al. Both Human Immunodeficiency Virus Cellular DNA Sequencing and Plasma RNA Sequencing Are Useful for Detection of Drug Resistance Mutations in Blood Samples from Antiretroviral-Drug-Naive Patients , 2007, Journal of Clinical Microbiology.
[12] C. Scagnolari,et al. Genotypic Resistance of Archived and Circulating Viral Strains in the Blood of Treated HIV-Infected Individuals , 2007, Journal of acquired immune deficiency syndromes.
[13] M. Re,et al. Genotypic resistance in plasma and peripheral blood lymphocytes in a group of naive HIV-1 patients. , 2007, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[14] Allan E. Rodriguez,et al. Prevalence of Antiretroviral Drug Resistance and Resistance-Associated Mutations in Antiretroviral Therapy-Naïve HIV-Infected Individuals from 40 United States Cities , 2007, HIV clinical trials.
[15] Gitte Pedersen,et al. Survival of Persons with and without HIV Infection in Denmark, 19952005 , 2007, Annals of Internal Medicine.
[16] M. Mcclure,et al. Prevalence of primary genotypic resistance in a UK centre: comparison of primary HIV-1 and newly diagnosed treatment-naive individuals , 2007, AIDS.
[17] W. Mcfarland,et al. Routine surveillance for the detection of acute and recent HIV infections and transmission of antiretroviral resistance , 2006, AIDS.
[18] John T Brooks,et al. Mortality in the Highly Active Antiretroviral Therapy Era: Changing Causes of Death and Disease in the HIV Outpatient Study , 2006, Journal of acquired immune deficiency syndromes.
[19] P. Harrigan,et al. Emergence of Drug Resistance Is Associated with an Increased Risk of Death among Patients First Starting HAART , 2006, PLoS medicine.
[20] M. Poljak,et al. Prevalence of antiretroviral drug resistance mutations and HIV-1 non-B subtypes in newly diagnosed drug-naïve patients in Slovenia, 2000-2004. , 2006, Virus research.
[21] Klaus Korn,et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. , 2005, The Journal of infectious diseases.
[22] R. Shafer,et al. Detection of Minority Populations of HIV-1 Expressing the K103N Resistance Mutation in Patients Failing Nevirapine , 2005, Journal of acquired immune deficiency syndromes.
[23] D. Pillay,et al. Transmission of HIV-1 drug resistance. , 2004, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[24] K. Metzner,et al. Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. , 2003, The Journal of infectious diseases.
[25] A. Moorman,et al. Factors associated with maintenance of long-term plasma human immunodeficiency virus RNA suppression. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[26] A. Mocroft,et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study , 2003, The Lancet.
[27] Elizabeth Connick,et al. Antiretroviral-drug resistance among patients recently infected with HIV. , 2002, The New England journal of medicine.
[28] J. Kahn,et al. Time trends in primary HIV-1 drug resistance among recently infected persons. , 2002, JAMA.
[29] Diana D. Huang,et al. Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program. , 2002, AIDS research and human retroviruses.
[30] C. Boucher,et al. Worldwide Evaluation of DNA Sequencing Approaches for Identification of Drug Resistance Mutations in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase , 1999, Journal of Clinical Microbiology.